Geodon in Weight Loss Study for Bipolar Disorders
Completed · Phase 4
Conditions studied: Bipolar Disorder
In brief
This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder. There will be approximately 25 patients enrolled in this study.
Key facts
- Study ID
- NCT00472641
- Run by
- Stanford University
- People needed
- 25
- Starts
- 2007-01-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2017-05-09
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.